Esperion Therapeutics, Inc. (ESPR)
| Previous close | 1.5500 |
| Open | 1.5000 |
| Bid | 1.5700 x 1300 |
| Ask | 1.5800 x 3200 |
| Day's range | 1.4600 - 1.6300 |
| 52-week range | 1.2600 - 8.8700 |
| Volume | |
| Avg. volume | 3,379,320 |
| Market cap | 121.368M |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 01 May 2023 - 05 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.55 |
- Simply Wall St.
Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers
The latest analyst coverage could presage a bad day for Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), with the analysts...
- Zacks
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
- Investing.com
5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' | Pro Recap
Atlantic Equities downgraded First Republic Bank (NYSE:FRC) to Neutral from Overweight - and it is withdrawing its price target on the stock, as "the exceptionally high level of uncertainty makes providing forecasts challenging." Wedbush likewise downgraded the shares, although JPMorgan reiterated the stock as a Top Pick and its Overweight rating on First Republic, saying it sees "considerable" EPS upside after the largest U.S. banks - Bank of America (NYSE:BAC), Citigroup (NYSE:C), JPMorgan (NYSE:JPM), and Wells Fargo (NYSE:WFC), among others - committed $30 billion in uninsured deposits to boost First Republic's liquidity. Esperion Therapeutics (NASDAQ:ESPR) was downgraded at Northland Capital Markets and BofA Securities after the company reported that Daiichi Sankyo Europe (DSE), its European partner, disagrees with its assessment that CLEAR Outcomes data would support milestone payments.
